Summary
A new 5-fluorouracil (5-FU) derivative, l-hexylcarbamoyl-5-fluorouracil (HCFU), has been developed in the National Cancer Center, and its phase I study is being performed in Japan by a clinical study group involving major institutions. Its LD50 values are nearly equal to those of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) and greater than those of 5-FU, and this compound is more effective than the latter two analogues against various experimental murine tumor systems. In the phase I study, the incidence ratio of side effects was dose dependent, and the characteristic subjective symptoms were hot sensation and pollakisuria. No hematologic or serum biochemical changes were noted.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Freireich, E. J., Gehan, E. A., Rall, A. P., Schmidt, L. H., Skipper, H. E.: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep. 50, 219 (1966)
Goldsmith, M. A., Slavic, M., Carter, S. K.: Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res. 35, 1354 (1975)
Hoshi, A., Iigo, M., Nakamura, A., Yoshida, M., Kuretani, K.: Antitumor activity of 1-hexyl-carbamoyl-5-fluorouracil in a variety of experimental tumors. Gann 67, 725 (1976)
Hoshi, A., Iigo, M., Nakamura, A., Inomata, M., Kuretani, K.: Antitumor activity of 1-alkyl-carbamoyl derivatives of 5-fluorouracil against L1210 leukemia. J. Pharm. Dyn., in press
Iigo, M., Nakamura, A., Kuretani, K., Hoshi, A.: Distribution of 1-hexylcarbamoyl-5-fluorouracil in mouse tissues. Proceedings of the Japanese Cancer Association, the 36th Annual Meeting, Oct. 1977, Tokyo, P-140
Iigo, M., Hoshi, A., Nakamura, A., Kuretani, K.: Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in Lewis lung carcinoma and B16 melanoma. J. Pharm. Dyn. 1, 49–54 (1978)
Maruyama, K., Okabayashi, K., Okazaki, N., Takakura, K., Sakano, T., Ise, Y., Ueki, K., Koyama, Y., Kuretani, K., Hoshi, A.: Clinical evaluation (phase 1 study) of a new anti-cancer drug 1-hexylcarbamoyl-5-fluorouracil (HCFU). J. Jap. Soc. Cancer Ther. 13 (4), 98 (1978)
Ozaki, S., Ike, Y., Mizuno, H., Ishikawa, K., Mori, H.: 5-Fluorouracil derivatives. 1. The synthesis of 1-carbamoyl-5-fluorouracils. Bull. Chem. Soc. Jpn. 50, 2406 (1977)
Tokuzen, R., Iigo, M., Hoshi, A., Kuretani, K.: Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma in mice. Proceedings of the Japanese Cancer Association, the 36th Annual Meeting, Oct. 1977, Tokyo, P-168
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Taguchi, T. (1980). Review of a New Antimetabolic Agent 1-Hexylcarbamoyl-5-Fluorouracil (HCFU). In: Carter, S.K., Sakurai, Y. (eds) New Anticancer Drugs. Recent Results in Cancer Research, vol 70. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81392-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-81392-4_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81394-8
Online ISBN: 978-3-642-81392-4
eBook Packages: Springer Book Archive